FDA Approves Genentech ’s Tecentriq plus Cotellic and Zelboraf for People With Advanced Melanoma

South San Francisco, CA -- July 30, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news